India I Equities

Company Update

FMEG

Change in Estimates ☑ Target ☑ Reco □

22 July 2020

Polycab, India

Strongly placed in a tough FY21; retaining a Buy

Polycab's weak Q1 was operationally in line with our estimates. B2C/tier 1-2 markets did better than B2B/metros. While FY21 will be tough, strategic steps to improve working capital and cost optimisation will offer long-run benefits. We remain positive on Polycab, given its leadership in the fast-growing C&W (incl. exports), wide distribution network, strong management and healthy balance sheet. Thus, we maintain a Buy with a target of ₹945 (17x/20x FY22e P/Es for C&W/FMEG), earlier ₹884. Profitable growth in FMEG will support a re-rating.

Weak, but operationally in line Q1. Revenue/EBITDA/PBT/PAT fell 50%/74%/80%/13% y/y because of all segments. Lower revenues impacted EBITDA margin (5.9% vs. 12.9% in FY20). Tax write-back related items (₹1bn) and a ₹97m gain on the Rayker consolidation helped to a lesser PAT decline. Otherwise, adj. PAT came at a meagre ₹75m (down 94% y/y). Despite this, net cash improved to ₹2.1bn after the release of WC since Apr.

Exports/wires/FMEG did better in Q1. While institutional supplies fell 80% y/y in Q1, the B2C segment (wires, FMEG) saw better traction with revenue share at 43% (vs. 35%). Revenues from tier 1-2 markets were higher at 55% (vs 40%) while metros were subdued. Exports, up 116% y/y, at ~₹1bn was without Dangote order (to be completed in the next 1-2 quarters).

Strategic moves to aid long-term sustainable growth. Focus on working capital management (inventory reduction, channel financing) and cost optimisation are a few strategic moves to keep Polycab on the sustainable growth path in the long run. ₹2bn capex in building capacities and technology upgrading, even in a tough FY21, is a testimonial to this.

Tough FY21, long-term prospects persist though. Over FY15-20, Polycab's revenue/PAT registered 13%/36% CAGRs. After a weak FY21, we expect a strong FY22 with return ratios returning to healthy levels. Despite short-term hiccups, the company's long-term prospects are bright.

Valuation. We maintain a Buy on Polycab, with a revised target of ₹945. **Key** risks: Volatile raw-material prices, slowdown in government spend on infra.

Key financials (YE Mar)	FY18	FY19	FY20	FY21e	FY22e		
Sales (₹ m)	67,703	79,560	88,300	71,277	102,683		
Net profit (₹ m)	3,525	5,003	7,717	5,432	8,070		
EPS (₹)	25.0	35.4	51.8	36.5	54.3		
PE (x)	33.0	23.3	15.9	22.6	15.2		
EV / EBITDA (x)	17.2	12.5	10.1	14.0	8.8		
PBV (x)	5.0	4.1	3.0	2.6	2.4		
RoE (%)	15.0	17.6	20.1	12.1	16.3		
RoCE (%) after tax	13.7	18.8	17.6	9.3	14.4		
Dividend yield (%)	0.1	0.4	0.8	0.6	1.2		
Net debt / equity (x)	0.3	-0.0	-0.1	-0.2	-0.1		
Source: Company, Anand Rathi Research							

Rating: **Buy**Target Price: ₹945
Share Price: ₹820

Key data	POLYCAB IN
52-week high / low	₹1182 / 525
Sensex / Nifty	37872 / 11133
3-m average volume	\$3.5m
Market cap	₹123bn / \$1642.1m
Shares outstanding	149m

Shareholding pattern (%)	Jun'20	Mar'20	Dec'19
Promoters	68.6	68.6	68.6
- of which, Pledged	-	-	-
Free float	31.5	31.4	31.4
- Foreign institutions	4.5	4.9	4.6
- Domestic institutions	12.9	13.2	13.4
- Public	14.0	13.3	13.4

Estimates revision (%)	FY21e	FY22e
Sales	(1)	1
EBITDA	8	1
PAT	34	1



Source: Bloomberg

Ashish Poddar Research Analyst

Devanshi Kapadia Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

Quick Glance – Financials and Valuations (Consol.)

Fig 1 – Income statement (₹ m)						
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e	
Net revenues	67,703	79,560	88,300	71,277	102,683	
Growth (%)	23.1	17.5	11.0	(19.3)	44.1	
Direct costs	50,894	57,117	63,686	52,391	75,254	
SG&A	9,608	13,211	13,263	11,177	14,919	
EBITDA	7,201	9,232	11,350	7,709	12,510	
EBITDA margins (%)	10.6	11.6	12.9	10.8	12.2	
- Depreciation	1,330	1,414	1,609	1,789	1,837	
Other income	644	933	928	636	440	
Interest expenses	937	1,167	495	418	290	
PBT	5,579	7,584	10,174	6,138	10,823	
Effective tax rate (%)	36.8	33.7	24.0	11.4	25.5	
+ Associates / (Minorities)	-	-	-	-	-	
Net income	3,525	5,003	7,717	5,432	8,070	
Adjusted income	3,525	5,003	7,717	5,432	8,070	
WANS	141	141	149	149	149	
FDEPS (₹ / sh)	25.0	35.4	51.8	36.5	54.3	
FDEPS growth (%)	51.2	41.9	46.3	(29.5)	48.6	
Gross margins (%)	24.8	28.2	27.9	26.5	26.7	

Fig 2 – Balance sheet (₹ m)							
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e		
Share capital	1,412	1,412	1,489	1,486	1,486		
Net worth	23,476	28,470	38,364	44,828	49,369		
Debt	7,277	1,920	1,221	1,241	1,241		
Minority interest	40	84	150	195	254		
DTL / (Assets)	553	231	175	165	155		
Capital employed	31,347	30,705	39,910	46,429	51,018		
Net tangible assets	11,944	12,721	13,865	14,272	14,930		
Net intangible assets	27	35	355	360	365		
Goodwill	-	-	-	-	-		
CWIP (tang. & intang.)	1,360	1,930	2,412	2,212	2,012		
Investments (strategic)	314	294	255	245	235		
Investments (financial)	1	-	400	7,400	5,400		
Current assets (ex cash)	30,728	38,137	39,516	37,038	47,562		
Cash	106	3,166	2,813	2,053	2,637		
Current liabilities	13,134	25,578	19,706	17,149	22,122		
Working capital	17,594	12,558	19,810	19,888	25,440		
Capital deployed	31,347	30,705	39,910	46,429	51,018		
Contingent liabilities	5,269	4,309	3,477	-	-		

Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e
EBIT (before other income)	5,872	7,817	9,741	5,920	10,673
+ Non-cash items	1,330	1,414	1,609	1,789	1,837
Oper. prof. before WC	7,201	9,232	11,350	7,709	12,510
- Incr. / (decr.) in WC	3,443	(5,167)	6,363	(422)	5,052
Others incl. taxes	1,056	3,083	3,726	1,596	3,653
Operating cash-flow	2,702	11,316	1,261	6,534	3,805
- Capex (tang. + intang.)	1,728	2,769	3,555	2,000	2,300
Free cash-flow	974	8,547	(2,294)	4,534	1,505
Acquisitions					
- Div. (incl. buyback & taxes)	169	508	1,251	892	1,784
+ Equity raised	-	-	77	-	-
+ Debt raised	(931)	(5,357)	(699)	20	
- Fin investments	(13)	(22)	361	6,990	(2,010)
- Misc. (CFI + CFF)	82	(357)	(4,174)	(2,570)	1,147
Net cash-flow	(195)	3,060	(354)	(760)	584

Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e
P/E (x)	33.0	23.3	15.9	22.6	15.2
EV / EBITDA (x)	17.2	12.5	10.1	14.0	8.8
EV / Sales (x)	1.8	1.4	1.3	1.5	1.1
P/B (x)	5.0	4.1	3.0	2.6	2.4
RoE (%)	15.0	17.6	20.1	12.1	16.3
RoCE (%) - after tax	13.7	18.8	17.6	9.3	14.4
ROIC	13.8	19.7	25.1	14.3	17.9
DPS (₹ / sh)	1.0	3.0	7.0	5.0	10.0
Dividend yield (%)	0.1	0.4	0.8	0.6	1.2
Dividend payout (%) - incl. DDT	4.0	8.5	13.5	13.7	18.4
Net debt / equity (x)	0.3	(0.0)	(0.1)	(0.2)	(0.1)
Receivables (days)	74.3	67.4	66.1	75.0	65.0
Inventory (days)	73.6	91.6	79.6	90.0	85.0
Payables (days)	49.7	69.7	56.0	55.0	55.0
CFO:PAT %	76.7	226.2	16.3	120.3	47.1

Fig 5 - Price movement






Fig 6 – Segment-wise revenue break-up (Q1 FY21)





Financial highlights

(₹ m)	Q1 FY20	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	% Y/Y	% Q/Q	FY20	FY19	% Y/Y
Total Income	19,513	22,419	25,073	21,294	9,766	(50)	(54)	88,300	79,830	11
Raw material costs	14,278	16,449	18,190	14,769	7,097	(50)	(52)	63,686	59,660	7
Employee costs	920	924	915	899	812	(12)	(10)	3,657	3,002	22
Other expenses	2,079	2,329	2,577	2,620	1,282	(38)	(51)	9,606	7,666	25
EBITDA	2,236	2,717	3,391	3,006	575	(74)	(81)	11,350	9,502	19
Depreciation	385	395	407	422	443	15	5	1,609	1,414	14
Finance costs	123	127	86	159	163	32	2	495	1,167	(58)
Other income	336	124	3	465	336	0	(28)	928	664	40
Exceptional items	-	-	-	-	97	-	-	-	-	-
PBT	2,064	2,319	2,902	2,889	403	(80)	(86)	10,174	7,584	34
Tax	713	365	686	680	(785)	(210)	(215)	2,444	2,558	(4)
PAT	1,353	1,938	2,214	2,151	1,176	(13)	(45)	7,656	5,003	53
EPS (₹)	9.1	13.0	14.9	14.5	7.9	(13)	(45)	51.4	33.6	53
As % of total Income						bps y/y	bps q/q			Bps y/y
Gross margin	26.8	26.6	27.5	30.6	27.3	50	(331)	27.9	25.3	261
Employee costs	4.7	4.1	3.6	4.2	8.3	360	410	4.1	3.8	38
Other expenses	10.7	10.4	10.3	12.3	13.1	247	82	10.9	9.6	128
EBITDA margin	11.5	12.1	13.5	14.1	5.9	(557)	(823)	12.9	11.9	95
Depreciation	2.0	1.8	1.6	2.0	4.5	256	255	1.8	1.8	5
Other income	1.7	0.6	0.0	2.2	3.4	172	126	1.1	0.8	22
Finance costs	0.6	0.6	0.3	0.7	1.7	104	92	0.6	1.5	(90)
PBT	1.7	0.6	0.0	2.2	3.4	172	126	1,1	0.8	22
Effective tax rate	34.6	15.7	23.6	23.5	(194.9)			24.0	33.7	(970)
PAT	6.9	8.7	8.8	10.4	12.2	524	178	8.8	6.3	246
Segment revenues (₹ m)						% Y/Y	% Q/Q			% Y/Y
Wires & Cables	16,375	19,222	21,696	18,605	8,252	(50)	(56)	75,898	70,643	7
FMEG	2,401	1,956	2,166	1,833	1,378	(43)	(25)	8,356	6,433	30
Others	1,226	1,638	1,510	1,592	684	(44)	(57)	5,965	4,637	29
Total	20,001	22,816	25,373	22,030	10,314	(48)	(53)	90,219	81,713	10
Less: Inter segment revenue	271	410	398	362	424	57	17	1,441	1,348	7
Total revenue	19,730	22,406	24,975	21,668	9,889	(50)	(54)	88,778	80,365	10
Segment EBIT (%)						bps y/y	bps q/q			bps y/y
Wires & Cables	11.4	10.5	11.9	15.2	3.0	(841)	(1,224)	12.2	11.8	42
FMEG	3.7	3.3	0.6	0.1	(4.0)	(769)	(410)	2.0	1.2	86
Others	9.7	16.0	22.4	10.4	10.1	42	(25)	14.8	4.3	1,056
Total	10.3	10.3	11.6	13.7	2.6	(772)	(1,107)	11.5	10.7	74


Source: Company, Anand Rathi Research
* Note: Segment EBIT margin is as per reported numbers and not adjusted for the un-allocable expenses/income















Source; Company, Anand Rathi Research





Source: Company, Anand Rathi Research





Source; Company, Anand Rathi Research

Source; Company, Anand Rathi Research


Valuation

After becoming the leader in wires & cables, in 2015 Polycab entered FMEG. We like it for its large manufacturing base, all-India distribution reach, induction of professional management, strong promoter family and focus on cash-flow. We believe all these factors, and its efforts to reposition itself as a consumer company, would drive a stock re-rating.

Over FY15-20, revenue/EBITDA/PAT registered 13%/21%/36% CAGRs. After anticipating a weak FY21, we now expect 8%/5%/2% CAGRs over FY20-22 with the RoE touching a healthy ~16% and FCF continuing.

While short-term challenges to growth persist, we are upbeat about Polycab's long-term prospects in W&C, strong growth in FMEGs and a healthy balance sheet. Thus, we maintain a Buy, with a higher target price of ₹945 (17x/20x FY22e P/Es for W&C/FMEG), earlier ₹884. To its FMEG business we assign a lower multiple than to those of leading players due to its smaller size and weaker operating matrices. However, a strong rerating is possible if it delivers strong profitable growth in coming years.

Fig 17 - Change in	n estimates						
	Old estim	ates	New estim	ates	% Var		
(₹m)	FY21e	FY22e	FY21e	FY22e	FY21e	FY22e	
Total Income	71,644	102,018	71,277	102,683	(1)	1	
EBITDA	7,122	12,381	7,709	12,510	8	1	
EBITDA margin %	9.9	12.1	10.8	12.2			
PAT	4,068	8,027	5,432	8,070	34	1	
Source: Anand Rathi Resea	ırch						



Risks


- Volatile raw-material prices: Copper and aluminium are key raw materials in W&C, constituting ~70% of costs. Any substantial volatility in raw-material prices would lead to operating-margin fluctuations and, thus, pose a key risk to our estimates.
- Slowdown in government's infra push: The government's push to infra has been a key growth driver for W&C in the past few years. Hence, any slowdown in government spending on infra could significantly cut into Polycab's growth, especially given its huge investment in capacity and branding.

Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies Rating and Target Price History (as of 22 July 2020)



Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)				
, ,	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps (<us\$1bn)< td=""><td>>25%</td><td>5-25%</td><td><5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No	

Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- © 2019. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097. Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.